National Comprehensive Cancer Network

About NCCN

NCCN Guidelines and Compendium Updated

NCCN Flash Updates™ sent February 6, 2013

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Adult Cancer Pain. These NCCN Guidelines® are currently available as Version 1.2013.

  • Principles of Cancer Pain Management
    • Three new principles were added:
      • Goals of pain management are improved comfort and function.
      • Persistent cancer pain often requires treatment with regularly scheduled analgesics, and supplemental doses of analgesics are often required to manage breakthrough pain.
      • Optimize integrative interventions
  • Opioids and Risk Evaluation and Mitigation Strategy (REMS)
    • A revision was made to the following statement: "REMS programs are currently in place for all transmucosal fentanyl products, transdermal fentanyl products, transdermal buprenorphine (See Approved Risk Evaluation and Mitigation Strategies [REMS]), and in 2013 the FDA will introduce REMS starting with continuing education for morphine-naltrexone combination product, all extended-release opioids, and long-acting opioids (methadone). See FDA Questions and Answers for REMS for Extended-Release and Long-Acting Opioid Analgesics."
  • Miscellaneous Analgesics
    • A new page titled, "Miscellaneous analgesics" was added for tramadol, transdermal buprenorphine, and ketamine.
  • Non-Opioid Analgesics
    • The dosing of acetaminophen was clarified by adding: "Acetaminophen, 650 mg every 4 h or 1 g every 6 h (daily maximum 4 g/d) in adult patients with normal liver function."

For the complete updated versions of the NCCN Guidelines® and the NCCN Compendium®, please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.com.

To access free NCCN Guidelines mobile apps for iPhone and Android, visit NCCN.org/mobile.

Now Available! The Virtual Library of NCCN Guidelines are now formatted for iPad and Android. Visit NCCN.org/mobile/tablet.asp.